287 results
8-K
VBIVQ
VBI Vaccines Inc
2 Aug 24
VBI Vaccines Provides an Update on its Restructuring Proceedings
4:05pm
Israeli Insolvency Law, and other litigation and inherent risks involved in a bankruptcy process. Forward-looking statements are also subject
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
2 Aug 24
VBI Vaccines Provides an Update on its Restructuring Proceedings
4:05pm
harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities … Insolvency Law, and other litigation and inherent risks involved in a bankruptcy process, the Company’s ability to regain and maintain compliance
8-K
VBIVQ
VBI Vaccines Inc
30 Jul 24
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
10:28am
related to the Chapter 15, the CCAA proceedings, proceedings under Israeli Insolvency Law, and other litigation and inherent risks involved
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
30 Jul 24
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
10:28am
of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 … related to the Chapter 15, the CCAA proceedings, and proceedings under Israeli Insolvency Law, and other litigation and inherent risks involved
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
29 May 24
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
8:00am
Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking
8-K
EX-1.1
lxnc 93d4f1tkb8jad56
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
8-K
EX-99.1
f0dk4rycok0d
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
424B5
azgwym3pgl7e2tlaa5
15 May 24
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
1uexjo
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
8-K
EX-10.1
jreb19b3e
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-99.1
9nnfq6 ket
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-99.2
6je02d9
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
plmct9fjk3otggbbl
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
EX-99.1
rijym jkn93t8
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
8-K
EX-99.1
hbwtn
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
8-K
EX-99.1
luf4br55xsndvr6zz
14 Feb 24
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
8:34am